arrow
A

Anna D. Staniszewska

AstraZeneca
H指数:20
被引数:1,829

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

乳腺癌的同源重组缺陷和半合子驱动抵抗

Nature
IF48.5
2026-03-040
OAAI
Subtype selective PET imaging of PARP1 binding in non-human primates, healthy volunteers and patients with glioblastoma using [11C]AZ14193391
2025-12-230
PRE
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair

雄激素受体抑制在前列腺癌模型中扩展了PARP抑制剂的活性,超越了BRCA突变和同源重组修复缺陷。

2025-12-010
OAAI
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor
2024-12-100
PRE
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1
2023-11-158
PRE
Preclinical evaluation of a novel B7-H4 targeted antibody-drug conjugate AZD8205 as a single agent and in combination with novel PARP inhibitor and checkpoint blockade
2023-04-040
PRE
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
2022-11-1030
OA
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
2022-10-148
OAAI
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper br
2022-08-0574
OAAI
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
2021-09-2781
PREAI